Sesen Bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sesen Bio, Inc.
The company, after revealing in May that it was evaluating various partnership or buyout strategies, also said it would sell its IL-6 programs to Roche as it pauses Vicineum’s US development.
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Keeping Track: Ticovac Is Latest Win For Pfizer’s Vaccine Business; Doors Open For BMS And GSK PD-1 Inhibitors
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
A complete response letter from the FDA has dashed Sesen Bio’s hopes of being first with a therapy for treating BCG-unresponsive non-muscle invasive bladder cancer. Its CEO says the FDA’s move may reflect heightened ‘pressure’ regulator is under.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Eleven Biotherapeutics, Inc.
- Viventia Bio Inc.